AstraZeneca (AstraZeneca) EBIT per Share : $2.91 (TTM As of Mar. 2024)

View and export this data going back to 1993. Start your Free Trial

What is AstraZeneca EBIT per Share?

AstraZeneca's EBIT per Share for the three months ended in Mar. 2024 was $1.03. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $2.91.

During the past 12 months, the average EBIT per Share Growth Rate of AstraZeneca was 85.70% per year. During the past 3 years, the average EBIT per Share Growth Rate was 25.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for AstraZeneca's EBIT per Share or its related term are showing as below:

AZN' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -41.6 Med: 7.9 Max: 32.6
Current: 25.7

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of AstraZeneca was 32.60% per year. The lowest was -41.60% per year. And the median was 7.90% per year.

AZN's 3-Year EBIT Growth Rate is ranked better than
74.06% of 852 companies
in the Drug Manufacturers industry
Industry Median: 8.05 vs AZN: 25.70

AstraZeneca's EBIT for the three months ended in Mar. 2024 was $3,213 Mil.

AstraZeneca EBIT per Share Historical Data

The historical data trend for AstraZeneca's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AstraZeneca EBIT per Share Chart

AstraZeneca Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

1.13

1.98

0.35

1.23

2.72

AstraZeneca Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT per Share	Get a 7-Day Free Trial															0.84	0.81	0.66	0.42	1.03

AstraZeneca EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

AstraZeneca's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	8488	/	3124.000
=	2.72

AstraZeneca's EBIT per Share for the quarter that ended in Mar. 2024 is calculated as

	EBIT per Share		(Q: Mar. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	3213	/	3120.000
=	1.03

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.91

AstraZeneca (NAS:AZN) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

AstraZeneca EBIT per Share Related Terms

Thank you for viewing the detailed overview of AstraZeneca's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

AstraZeneca (AstraZeneca) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AstraZeneca PLC (NAS:AZN) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

AZNCF:USA AZN:Sweden AZNN:Mexico AZNl:UK AZN:UK ZEGA:Germany ZEG:Germany ZEG:Germany ZEG:Germany ZEGA:Germany ZEG:Germany A1ZN34:Brazil

Address

1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AA

Website

https://www.astrazeneca.com

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its revenue.